Alain Delmer

Professor of Hematology

France

Research Interests

Explore related searches

Professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Alain Delmer is a Professor of Hematology at Université de Reims Champagne-Ardenne UFR de Médecine in France. His research focuses on various aspects of hematological malignancies, including chronic lymphocytic leukemia, anaplastic large-cell lymphoma, and follicular lymphoma. He has contributed to significant studies on treatment efficacy, disease transformation, and molecular characterization of various leukemias. His recent publications reflect a commitment to advancing the understanding and management of these complex conditions.

Articles (18)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (4)

Damien Luque Paz

FRANCE

View details

Cécile Tomowiak

FRANCE

View details

David Morland

Université de Reims Champagne-Ardenne

FRANCE

View details

Sébastien Hergalant

INSERM

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Alain Delmer

Research Interests

Explore related searches

Contact this professor

About

Articles (18)

Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis.

Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.

Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial.

First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia

Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study).

Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia.

Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab.

Born in the UK: A registry to improve and broadcast knowledge on Waldenström macroglobulinaemia.

Transformed Waldenström Macroglobulinemia: Update on Diagnosis, Prognosis and Treatment

Feasibility and Impact of Adapted Physical Activity (APA) in Cancer Outpatients Beginning Medical Anti-Tumoral Treatment: The UMA-CHAPA Study

High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia.

Cerebellum/liver index in pretherapeutic 18F-FDG PET/CT as a predictive marker of progression-free survival in follicular lymphoma treated by immunochemotherapy and rituximab maintenance.

Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.

Frontline treatment in CLL: the case for time-limited treatment.

Watch and wait in Waldenström macroglobulinaemia: looking for who to watch carefully and who can wait without worrying. Is it that simple?

Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO).

18F-FDG cerebellum/liver index as a prognostic factor for progression-free survival in diffuse large B-cell lymphoma.

Collaborators (4)

Damien Luque Paz

Cécile Tomowiak

David Morland

Sébastien Hergalant

Make your next move.